NEW YORK (GenomeWeb) – Foundation Medicine after the close of market Tuesday reported a 54 percent increase in revenues for the third quarter, driven by strong growth from its biopharmaceutical business, along with a widening net loss and a sequential decrease in the number of clinical tests it provided.

Investors reacted negatively to the shortfall in clinical tests and a lowered forecast for 2015 clinical test volume, sending Foundation Medicine’s shares down 21 percent in Wednesday morning trade on the Nasdaq to $18.91.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

Jul
19
Sponsored by
Philips Genomics

This webinar will provide an overview of how liquid biopsies can be integrated into lung cancer care.

Jul
20
Sponsored by
NuGEN

This webinar describes the characterization of gene fusions across distinct subtypes of melanoma.